Chinese researchers recently released results of the first clinical trial for hydroxychloroquine against COVID-19, showing that when used for coronavirus treatment, it could cause an adverse digestive reaction, reported the Global Times.
They said that using hydroxychloroquine for mild-to-moderate coronavirus-infected patients is not encouraged, as patients can show symptoms of digestive diseases, such as diarrhea, sickness and vomiting.
The research, which was published in the BMJ, was based on a total of 150 admitted confirmed COVID-19 patients.
One group of 75 people were initially given a daily dosage of 1200 mg of hydroxychloroquine for three days, and later 800 mg every day for two weeks. Another group of 75 were given only standard care.
"There were no significant differences between the two groups," said Xie Qing, director of the infectious disease department at the Ruijin hospital.
Apart from some adverse effects, no severe reactions were seen in either group of patients, the researcher noted.
To read more NewsPoints articles, click here.